reviewThe Lancet Infectious DiseasesMar 1, 2003Closed access

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

MGMichael GardamEKEdward KeystoneRMRichard MenziesSMS MannersESEmil Skamene

University Health Network · Sinai Hospital · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

751
total citations
FWCI
29.98
Percentile
100%
References
65
Citations per year

Authors

7

Topics & keywords

Topics
Keywords
  • Medicine
  • Infliximab
  • Tuberculosis
  • Etanercept
  • Tuberculin
  • Tumor necrosis factor alpha
  • Latent tuberculosis
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.